Antibiotic trial aims to shrink fatty livers
NCT ID NCT07185932
Summary
This early-stage study is testing whether the antibiotic rifaximin can safely reduce liver fat in people with metabolic-associated fatty liver disease (MAFLD). Up to 40 participants will take the drug daily for 24 weeks while maintaining their usual diet and exercise. The main goal is to see if the treatment lowers liver fat content measured by MRI scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC-ASSOCIATED FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changzheng Hospital, Naval Medical University, shanghai, China
RECRUITINGShanghai, Shanghai Municipality, 200003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.